logo
Plus   Neg
Share
Email

Biogen CEO Confident Its Alzheimer's Drug Will Get FDA Approval

Biogen Inc. (BIIB) reportedly are "reasonably confident" that the U.S. Food and Drug Administration will approve its experimental Alzheimer's drug.

According to CNBC, Biogen CEO Michel Vounatsos told that he is "reasonably confident" of receiving approval from FDA for aducanumab, its experimental Alzheimer's drug.

"We worked in full transparency with the regulator," Vounatsos told "Squawk Box," emphasizing the FDA has all of the company's data on the drug.

"The evidence came over time. We collected a tremendous and complex set of data, including biomarkers and imaging," he said. "This was a thorough engagement, and as CEO I'm reasonably confident this will lead to market approval one day."

Shares of Biogen surged about 26% on Tuesday after the drugmaker announced plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer's disease. The decision is based on a new analysis, conducted by Biogen in consultation with the FDA, of a larger dataset from the Phase 3 clinical studies that were discontinued in March 2019.

Biogen plans to file a Biologics License Application in early 2020. The company said it will continue dialogue with regulatory authorities including those in Europe and Japan.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tesla said it will produce ventilators at its Gigafactory in Buffalo, New York to support the city's hospitals amid the coronavirus pandemic. New York is the worst affected state in the U.S. Last Saturday, Musk tweeted that he "had a long engineering discussion with Medtronic about state-of-the-art ventilators. Luxury fashion house Ralph Lauren will donate $10 million to help fight the coronavirus pandemic and manufacture face masks as well as medical gowns in the U.S. The company's charity arm, the Ralph Lauren Corporate Foundation, said in a statement that it is committing $10 million towards the global response to the COVID-19 pandemic. General Motors Co. is delaying work on new vehicle models and is cutting pay for its executives as part of efforts to conserve cash amid the coronavirus or Covid-19 pandemic. The automotive giant also extended the shutdown of North American plants indefinitely. Multiple reports cited an internal memo that salaried workforce will have 20 percent of pay deferred starting April 1.
Follow RTT
>